NasdaqGS:XON

Stock Analysis Report

Executive Summary

Intrexon Corporation engages in the engineering and industrialization of biology in the United States.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Intrexon's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.0%

XON

1.7%

US Biotechs

1.3%

US Market


1 Year Return

-61.0%

XON

-8.8%

US Biotechs

5.9%

US Market

Return vs Industry: XON underperformed the US Biotechs industry which returned -8.8% over the past year.

Return vs Market: XON underperformed the US Market which returned 5.9% over the past year.


Shareholder returns

XONIndustryMarket
7 Day-2.0%1.7%1.3%
30 Day-7.9%-3.5%-1.9%
90 Day-22.0%-3.1%-1.8%
1 Year-61.0%-61.0%-8.0%-8.8%8.3%5.9%
3 Year-77.6%-77.6%13.9%9.9%45.6%36.2%
5 Year-68.4%-68.5%3.8%-1.2%66.1%47.9%

Price Volatility Vs. Market

How volatile is Intrexon's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Intrexon undervalued compared to its fair value and its price relative to the market?

3.43x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate XON's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate XON's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: XON is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: XON is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate XON's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XON is overvalued based on its PB Ratio (3.4x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Intrexon forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

52.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XON is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XON is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XON is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XON's revenue is expected to decline over the next 3 years (-21.4% per year).

High Growth Revenue: XON's revenue is forecast to decline over the next 3 years (-21.4%).


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: XON is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Intrexon performed over the past 5 years?

-39.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: XON is unprofitable, and losses have increased over the past 5 years at a rate of -39.7% per year.

Accelerating Growth: Unable to compare XON's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: XON has a negative Return on Equity (-179.62%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: XON is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: XON is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Intrexon's financial position?


Financial Position Analysis

Short Term Liabilities: XON's short term assets ($183.2M) exceeds its short term liabilities ($51.6M)

Long Term Liabilities: XON's short term assets (183.2M) do not cover its long term liabilities (324.3M)


Debt to Equity History and Analysis

Debt Level: XON's debt to equity ratio (76.4%) is considered high

Reducing Debt: XON had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: XON has a high level of physical assets or inventory.

Debt Coverage by Assets: XON's debt is not covered by short term assets (assets are 0.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XON has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: XON has sufficient cash runway for 2.037566 years if free cash flow continues to reduce at historical rates of -42% each year.


Next Steps

Dividend

What is Intrexon's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate XON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XON's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if XON's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XON's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XON's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Intrexon's salary, the management and board of directors tenure and is there insider trading?

6.4yrs

Average management tenure


CEO

RJ Kirk (66yo)

10.5yrs

Tenure

US$2,056,450

Compensation

Mr. Randal J. Kirk, also known as RJ, J.D., has been the Chief Executive Officer of Intrexon Corporation since April 2009. Mr. Kirk served as President of Intrexon Corporation since April 2009. He served a ...


Management Age and Tenure

6.4yrs

Average Tenure

56yo

Average Age

Experienced Management: XON's management team is seasoned and experienced (6.4 years average tenure).


Board Age and Tenure

9.3yrs

Average Tenure

64yo

Average Age

Experienced Board: XON's board of directors are considered experienced (9.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$4,223,60610 Jun 19
Third Security, LLC
EntityCompany
Shares805,447
Max PriceUS$5.26
BuyUS$1,663,78504 Jun 19
Third Security, LLC
EntityCompany
Shares338,869
Max PriceUS$5.17
BuyUS$3,919,50230 May 19
Third Security, LLC
EntityCompany
Shares825,451
Max PriceUS$4.79
BuyUS$3,202,00724 May 19
Third Security, LLC
EntityCompany
Shares683,417
Max PriceUS$4.70
BuyUS$4,915,17122 May 19
Third Security, LLC
EntityCompany
Shares1,056,054
Max PriceUS$4.74
BuyUS$5,215,17515 May 19
Third Security, LLC
EntityCompany
Shares1,153,878
Max PriceUS$4.59
BuyUS$4,004,90715 May 19
Third Security, LLC
EntityCompany
Shares942,331
Max PriceUS$4.25
SellUS$954,40807 Mar 19
Thomas Reed
EntityIndividual
Role
Top Key Executive
Founder & Chief Science Officer
Shares227,800
Max PriceUS$4.66
SellUS$190,67103 Jan 19
Thomas Reed
EntityIndividual
Role
Top Key Executive
Founder & Chief Science Officer
Shares30,000
Max PriceUS$6.36

Ownership Breakdown


Management Team

  • RJ Kirk (66yo)

    Chairman & CEO

    • Tenure: 10.5yrs
    • Compensation: US$2.06m
  • Thomas Reed (53yo)

    Founder & Chief Science Officer

    • Tenure: 21.8yrs
    • Compensation: US$572.72k
  • Bob Walsh (61yo)

    Senior Vice President of Energy & Fine Chemicals Platforms

    • Tenure: 6.4yrs
    • Compensation: US$3.14m
  • Jeff Perez (47yo)

    Senior Vice President of Intellectual Property Affairs

    • Tenure: 5.2yrs
    • Compensation: US$3.22m
  • Rick Sterling (55yo)

    Chief Financial Officer

    • Tenure: 12.8yrs
    • Compensation: US$1.12m
  • Don Lehr (44yo)

    Chief Legal Officer & Corporate Secretary

    • Tenure: 8.8yrs
    • Compensation: US$1.23m
  • Helen Sabzevari (57yo)

    President of Precigen

    • Tenure: 1.9yrs
    • Compensation: US$2.72m
  • Tom Bostick (62yo)

    Chief Operating Officer

    • Tenure: 1.9yrs
  • Marie Rossi

    Vice President of Communications

    • Tenure: 0yrs
  • Steven Harasym

    Vice President of Investor Relations

    • Tenure: 1.8yrs

Board Members

  • Jeff Kindler (63yo)

    Independent Director

    • Tenure: 7.9yrs
    • Compensation: US$318.99k
  • Fred Hassan (73yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$306.48k
  • Cesar Alvarez (71yo)

    Independent Director

    • Tenure: 11.7yrs
    • Compensation: US$312.49k
  • Robert Shapiro (80yo)

    Lead Independent Director

    • Tenure: 0yrs
    • Compensation: US$312.99k
  • RJ Kirk (66yo)

    Chairman & CEO

    • Tenure: 10.5yrs
    • Compensation: US$2.06m
  • Jim Turley (64yo)

    Independent Director

    • Tenure: 5.5yrs
    • Compensation: US$312.48k
  • Dean Mitchell (63yo)

    Independent Director

    • Tenure: 10.6yrs
    • Compensation: US$306.48k
  • Steven Frank (59yo)

    Independent Director

    • Tenure: 11.7yrs
    • Compensation: US$299.98k
  • Vinita Gupta (51yo)

    Independent Director

    • Tenure: 2.5yrs
    • Compensation: US$306.48k

Company Information

Intrexon Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Intrexon Corporation
  • Ticker: XON
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$957.837m
  • Shares outstanding: 162.07m
  • Website: https://www.dna.com

Number of Employees


Location

  • Intrexon Corporation
  • 20374 Seneca Meadows Parkway
  • Germantown
  • Maryland
  • 20876
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XONNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 2013
I5XDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2013

Biography

Intrexon Corporation engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regul ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 00:27
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.